Logo image of LEN.DE

LENZING AG (LEN.DE) Stock Fundamental Analysis

FRA:LEN - Deutsche Boerse Ag - AT0000644505 - Common Stock - Currency: EUR

27.9  +0.35 (+1.27%)

Fundamental Rating

2

Taking everything into account, LEN scores 2 out of 10 in our fundamental rating. LEN was compared to 62 industry peers in the Chemicals industry. LEN has a bad profitability rating. Also its financial health evaluation is rather negative. LEN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

LEN had negative earnings in the past year.
In the past year LEN had a positive cash flow from operations.
In multiple years LEN reported negative net income over the last 5 years.
Of the past 5 years LEN 4 years had a positive operating cash flow.
LEN.DE Yearly Net Income VS EBIT VS OCF VS FCFLEN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

The Return On Assets of LEN (-3.15%) is worse than 62.90% of its industry peers.
With a Return On Equity value of -11.96%, LEN is not doing good in the industry: 66.13% of the companies in the same industry are doing better.
LEN has a Return On Invested Capital (1.60%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for LEN is below the industry average of 6.15%.
The last Return On Invested Capital (1.60%) for LEN is above the 3 year average (1.29%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -3.15%
ROE -11.96%
ROIC 1.6%
ROA(3y)-5.64%
ROA(5y)-2.94%
ROE(3y)-20.41%
ROE(5y)-11%
ROIC(3y)1.29%
ROIC(5y)1.63%
LEN.DE Yearly ROA, ROE, ROICLEN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

LEN's Operating Margin of 3.33% is in line compared to the rest of the industry. LEN outperforms 53.23% of its industry peers.
LEN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 19.07%, LEN is doing worse than 69.35% of the companies in the same industry.
In the last couple of years the Gross Margin of LEN has declined.
Industry RankSector Rank
OM 3.33%
PM (TTM) N/A
GM 19.07%
OM growth 3Y-21.19%
OM growth 5Y-11.81%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.92%
GM growth 5Y-14.28%
LEN.DE Yearly Profit, Operating, Gross MarginsLEN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LEN is destroying value.
LEN has about the same amout of shares outstanding than it did 1 year ago.
LEN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, LEN has an improved debt to assets ratio.
LEN.DE Yearly Shares OutstandingLEN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LEN.DE Yearly Total Debt VS Total AssetsLEN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

LEN has an Altman-Z score of 1.10. This is a bad value and indicates that LEN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.10, LEN is doing worse than 72.58% of the companies in the same industry.
The Debt to FCF ratio of LEN is 12.69, which is on the high side as it means it would take LEN, 12.69 years of fcf income to pay off all of its debts.
LEN's Debt to FCF ratio of 12.69 is in line compared to the rest of the industry. LEN outperforms 53.23% of its industry peers.
A Debt/Equity ratio of 1.40 is on the high side and indicates that LEN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.40, LEN is doing worse than 77.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.4
Debt/FCF 12.69
Altman-Z 1.1
ROIC/WACC0.26
WACC6.05%
LEN.DE Yearly LT Debt VS Equity VS FCFLEN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

LEN has a Current Ratio of 1.48. This is a normal value and indicates that LEN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.48, LEN is in line with its industry, outperforming 40.32% of the companies in the same industry.
LEN has a Quick Ratio of 1.48. This is a bad value and indicates that LEN is not financially healthy enough and could expect problems in meeting its short term obligations.
LEN has a worse Quick ratio (0.89) than 61.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 0.89
LEN.DE Yearly Current Assets VS Current LiabilitesLEN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

3

3. Growth

3.1 Past

LEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.56%, which is quite impressive.
LEN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.67%.
LEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.82% yearly.
EPS 1Y (TTM)76.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.69%
Revenue 1Y (TTM)5.67%
Revenue growth 3Y6.67%
Revenue growth 5Y4.82%
Sales Q2Q%7.68%

3.2 Future

LEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.54% yearly.
The Revenue is expected to grow by 2.54% on average over the next years.
EPS Next Y104.55%
EPS Next 2Y107.39%
EPS Next 3Y60.99%
EPS Next 5Y44.54%
Revenue Next Year8.17%
Revenue Next 2Y6.14%
Revenue Next 3Y5.77%
Revenue Next 5Y2.54%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LEN.DE Yearly Revenue VS EstimatesLEN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
LEN.DE Yearly EPS VS EstimatesLEN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEN. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 637.52, which means the current valuation is very expensive for LEN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LEN indicates a slightly more expensive valuation: LEN is more expensive than 66.13% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.38, LEN is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 637.52
LEN.DE Price Earnings VS Forward Price EarningsLEN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LEN indicates a somewhat cheap valuation: LEN is cheaper than 77.42% of the companies listed in the same industry.
96.77% of the companies in the same industry are more expensive than LEN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 6.48
EV/EBITDA 6.71
LEN.DE Per share dataLEN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LEN does not grow enough to justify the current Price/Earnings ratio.
LEN's earnings are expected to grow with 60.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y107.39%
EPS Next 3Y60.99%

0

5. Dividend

5.1 Amount

LEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

LENZING AG

FRA:LEN (4/28/2025, 7:00:00 PM)

27.9

+0.35 (+1.27%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)03-14 2025-03-14/amc
Earnings (Next)05-08 2025-05-08
Inst Owners19.14%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.08B
Analysts51.67
Price Target32.6 (16.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.74
Dividend Growth(5Y)-31.68%
DP-18.36%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.88%
PT rev (3m)-3.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)99.95%
EPS NY rev (3m)157.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)4.76%
Revenue NY rev (3m)1.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 637.52
P/S 0.4
P/FCF 6.48
P/OCF 3.34
P/B 0.82
P/tB 0.84
EV/EBITDA 6.71
EPS(TTM)-4.06
EYN/A
EPS(NY)0.04
Fwd EY0.16%
FCF(TTM)4.3
FCFY15.42%
OCF(TTM)8.35
OCFY29.93%
SpS68.98
BVpS33.92
TBVpS33.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.15%
ROE -11.96%
ROCE 2.28%
ROIC 1.6%
ROICexc 1.83%
ROICexgc 1.84%
OM 3.33%
PM (TTM) N/A
GM 19.07%
FCFM 6.24%
ROA(3y)-5.64%
ROA(5y)-2.94%
ROE(3y)-20.41%
ROE(5y)-11%
ROIC(3y)1.29%
ROIC(5y)1.63%
ROICexc(3y)1.51%
ROICexc(5y)2.07%
ROICexgc(3y)1.52%
ROICexgc(5y)2.09%
ROCE(3y)1.84%
ROCE(5y)2.31%
ROICexcg growth 3Y-16.94%
ROICexcg growth 5Y-17.21%
ROICexc growth 3Y-16.83%
ROICexc growth 5Y-17.09%
OM growth 3Y-21.19%
OM growth 5Y-11.81%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.92%
GM growth 5Y-14.28%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 1.4
Debt/FCF 12.69
Debt/EBITDA 4.6
Cap/Depr 50.63%
Cap/Sales 5.87%
Interest Coverage 0.83
Cash Conversion 81.16%
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 0.89
Altman-Z 1.1
F-Score5
WACC6.05%
ROIC/WACC0.26
Cap/Depr(3y)130.66%
Cap/Depr(5y)264.56%
Cap/Sales(3y)14.58%
Cap/Sales(5y)24.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.69%
EPS Next Y104.55%
EPS Next 2Y107.39%
EPS Next 3Y60.99%
EPS Next 5Y44.54%
Revenue 1Y (TTM)5.67%
Revenue growth 3Y6.67%
Revenue growth 5Y4.82%
Sales Q2Q%7.68%
Revenue Next Year8.17%
Revenue Next 2Y6.14%
Revenue Next 3Y5.77%
Revenue Next 5Y2.54%
EBIT growth 1Y118.6%
EBIT growth 3Y-15.93%
EBIT growth 5Y-7.56%
EBIT Next Year510.81%
EBIT Next 3Y95.6%
EBIT Next 5Y67.42%
FCF growth 1Y254.56%
FCF growth 3YN/A
FCF growth 5Y207.34%
OCF growth 1Y101.16%
OCF growth 3Y-6.46%
OCF growth 5Y5.68%